Search

Your search keyword '"Sun, Sanyuan"' showing total 7 results
Start Over Author "Sun, Sanyuan" Publisher springer science and business media llc
7 results on '"Sun, Sanyuan"'

1. Umbrella strategy with systemic and intraperitoneal chemotherapy versus systemic chemotherapy in patients with advanced gastric cancer: a multicenter, randomized Phase III clinical trial

Author

Yang, Yang, primary, Wei, Jia, additional, Du, Juan, additional, Zou, Zhengyun, additional, Wei, Rongfu, additional, Zhang, Fenglin, additional, Shen, Weisheng, additional, Lu, Xiyan, additional, Sun, Sanyuan, additional, Li, Xiaoqin, additional, Nie, Chunlan, additional, Chen, Gang, additional, Yu, Lixia, additional, Qian, Hanqing, additional, Yang, Yan, additional, Liu, Qin, additional, Shen, Jie, additional, Wang, Lifeng, additional, Xing, Yajun, additional, Cui, Fangbo, additional, Shi, Jianmin, additional, Xi, Lei, additional, Deng, Lichun, additional, Cao, Xiangmin, additional, Zhu, Qing, additional, Yuan, Yuan, additional, Cheng, Meilian, additional, Xu, Hui, additional, Yuan, Ling, additional, Guo, Miaomiao, additional, Wang, Meng, additional, Gao, Changyan, additional, Qian, Xiaoping, additional, Guan, Wenxian, additional, and Liu, Baorui, additional

Published
2023
Full Text
View/download PDF

2. Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)

Author

Shi, Yuankai, primary, Chen, Jianhua, additional, Zhang, Helong, additional, Zhang, Zhihong, additional, Zhang, Yiping, additional, Wang, Zhehai, additional, Zhang, Shucai, additional, Zhao, Jian, additional, Liu, Chunling, additional, Wang, Xiuwen, additional, Zhao, Yanqiu, additional, Hu, Changlu, additional, Yang, Lei, additional, Hao, Xuezhi, additional, Wang, Lin, additional, Liu, Yunpeng, additional, Yu, Yan, additional, Zhao, Jun, additional, Wang, Mengzhao, additional, Zhang, Liangming, additional, Sun, Sanyuan, additional, Hu, Yanping, additional, Gu, Kangsheng, additional, Hang, Xiaosheng, additional, Shan, Jinlu, additional, Zhang, Yu, additional, Tan, Bangxian, additional, Yang, Weihua, additional, Yang, Runxiang, additional, Si, Meimei, additional, Geng, Huaize, additional, Li, Hui, additional, and Kang, Xiaoyan, additional

Published
2023
Full Text
View/download PDF

3. Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy

Author

Chen, Shanshan, primary, Han, Yiqun, additional, Ouyang, Quchang, additional, Lu, Jianguo, additional, Zhang, Qingyuan, additional, Yang, Shun’e, additional, Wang, Jingfen, additional, Huang, Haixin, additional, Liu, Hong, additional, Shao, Zhimin, additional, Li, Hui, additional, Chen, Zhendong, additional, Sun, Sanyuan, additional, Geng, Cuizhi, additional, Lu, Junguo, additional, Sun, Jianwei, additional, Wang, Jiayu, additional, and Xu, Binghe, additional

Published
2021
Full Text
View/download PDF

4. Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial

Author

Li, Jin, primary, Guo, Weijian, additional, Bai, Yuxian, additional, Deng, Yanhong, additional, Yang, Lei, additional, Chen, Zhendong, additional, Zhong, Haijun, additional, Xu, Ruihua, additional, Pan, Hongming, additional, Shu, Yongqian, additional, Yuan, Ying, additional, Zhou, Jianfeng, additional, Xu, Nong, additional, Liu, Tianshu, additional, Ma, Dong, additional, Wu, Changping, additional, Cheng, Ying, additional, Xu, Jianming, additional, Chen, Donghui, additional, Li, Wei, additional, Sun, Sanyuan, additional, Yu, Zhuang, additional, Cao, Peiguo, additional, Shen, Lin, additional, Chen, Haihui, additional, Wang, Shubin, additional, Wang, Hongbing, additional, Fan, Songhua, additional, Guo, Xiaojun, additional, Wang, Ning, additional, Han, Rubing, additional, Zhang, Bin, additional, and Qin, Shukui, additional

Published
2020
Full Text
View/download PDF

5. A Relationship Between Replication Protein A and Occurrence and Prognosis of Esophageal Carcinoma

Author

Lu Hong, Zhao Di, Yu Dahai, Zhou Chong, and Sun Sanyuan

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Esophageal Neoplasms, Biophysics, Labeling index, Kaplan-Meier Estimate, Biology, Biochemistry, Text mining, Replication Protein A, Internal medicine, medicine, Carcinoma, Humans, Stage (cooking), Replication protein A, Aged, Neoplasm Staging, business.industry, DNA replication, Late stage, Cancer, Cell Biology, General Medicine, Middle Aged, Prognosis, medicine.disease, Immunohistochemistry, Lymphatic Metastasis, Multivariate Analysis, Female, business, Biomarkers
Abstract

Esophageal carcinoma (EC) is an aggressive and the third most common cancer of the digestive tract with poor prognosis. Replication protein A (RPA) is critically required for DNA replication and its elevated expression has been observed in many malignant tumors. In this study, we investigated the expression of RPA1 and RPA2, subunits of RPA, and assessed their prognostic value in EC patients. We analyzed immunohistochemically the expression of RPA1 and RPA2 proteins in 48 EC resection specimens in relation with clinicopathological parameters and survival. We observed a significant elevated (P < 0.001) RPA1 and RPA2 expressions (labeling index) in the tumor than adjacent non-tumor tissues. In addition, both RPA1 and RPA2 labeling index in lymph node metastasis patients was significantly higher (both P = 0.000) than patients without lymph node metastasis. However, RPA1 and RPA2 labeling index in early stage was significantly lower (P = 0.000 and P = 0.002, respectively) than that of late stage EC patients. Importantly, patient’s survival at early stage was significantly higher (P = 0.016) than late stage EC and lymph node metastasis and RPA1 expression was associated with adverse patient’s outcome in multivariate analysis (P < 0.05 and P < 0.00, respectively). In conclusion, RPA1 could be a useful prognostic indicator in patients with esophageal carcinoma and might be a future attractive therapeutic target for regulation by tumor suppressors.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results